Vanguard Investments Australia
BCAX

Vanguard Investments Australia’s Bicara Therapeutics BCAX Stock Holding History

Vanguard Investments Australia’s Portfolio BCAX Stock Details BCAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$221K Hold
7,427
– – ﹤0.01% 2074
2026
Q1 		$148K Buy
+7,427
New +$128K ﹤0.01% 2165

Other funds holding BCAX

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
RTM
Red Tree Management Redwood City, California $147M AUM 202.18% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
RPSM
Royalty Pharma Sub-Manager New York $242M AUM

Vanguard Investments Australia's BCAX Position: Q2 2026 in Review

Vanguard Investments Australia held its Bicara Therapeutics (BCAX) position steady in Q2 2026 at 7,427 shares worth $221K. The position accounts for ﹤0.01% of the portfolio, ranked #2074.

Vanguard Investments Australia first reported a position in BCAX in Q1 2026 and has held it in 2 quarters since. 157 funds tracked by Wall St. Rank hold BCAX as of Q2 2026.

  • Vanguard Investments Australia held 7,427 shares of Bicara Therapeutics worth $221K as of Q2 2026.
  • Vanguard Investments Australia left its Bicara Therapeutics share count unchanged in Q2 2026.
  • Bicara Therapeutics made up ﹤0.01% of Vanguard Investments Australia's portfolio in Q2 2026, its #2074 holding.
  • Vanguard Investments Australia first reported a position in Bicara Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 157 funds tracked by Wall St. Rank held Bicara Therapeutics as of Q2 2026.

Based on Vanguard Investments Australia's 13F filing for Q2 2026, filed 13 Aug 2026.